RecruitingPhase 1NCT06280482
Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
Studying Multisystemic smooth muscle dysfunction syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The University of Texas Health Science Center, Houston
- Principal Investigator
- Dianna Milewicz, MD, PhDThe University of Texas Health Science Center, Houston
- Intervention
- Nicotinamide riboside (NR)(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- The University of Texas Health Science Center at Houston, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06280482 on ClinicalTrials.govOther trials for Multisystemic smooth muscle dysfunction syndrome
Additional recruiting or active studies for the same condition.
See all trials for Multisystemic smooth muscle dysfunction syndrome →